HomeCompareVEDL vs JNJ

VEDL vs JNJ: Dividend Comparison 2026

VEDL yields 42.08% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VEDL wins by $22936321824.61M in total portfolio value
10 years
VEDL
VEDL
● Live price
42.08%
Share price
$16.50
Annual div
$6.94
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22936321824.65M
Annual income
$22,832,083,042,276,228.00
Full VEDL calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — VEDL vs JNJ

📍 VEDL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVEDLJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VEDL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VEDL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VEDL
Annual income on $10K today (after 15% tax)
$3,576.62/yr
After 10yr DRIP, annual income (after tax)
$19,407,270,585,934,790.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, VEDL beats the other by $19,407,270,585,930,810.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VEDL + JNJ for your $10,000?

VEDL: 50%JNJ: 50%
100% JNJ50/50100% VEDL
Portfolio after 10yr
$11468160912.34M
Annual income
$11,416,041,521,140,458.00/yr
Blended yield
99.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VEDL
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VEDL buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVEDLJNJ
Forward yield42.08%2.13%
Annual dividend / share$6.94$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$22936321824.65M$30.3K
Annual income after 10y$22,832,083,042,276,228.00$4,689.40
Total dividends collected$22929447725.05M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: VEDL vs JNJ ($10,000, DRIP)

YearVEDL PortfolioVEDL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$19,116$8,415.58$10,592$272.30+$8.5KVEDL
2$50,523$30,068.91$11,289$357.73+$39.2KVEDL
3$202,606$148,546.35$12,123$472.89+$190.5KVEDL
4$1,330,246$1,113,458.24$13,141$629.86+$1.32MVEDL
5$15,088,089$13,664,725.19$14,408$846.81+$15.07MVEDL
6$305,844,816$289,700,560.97$16,021$1,151.60+$305.83MVEDL
7$11,303,717,836$10,976,463,883.46$18,122$1,588.22+$11303.70MVEDL
8$770,373,675,735$758,278,697,649.93$20,930$2,228.20+$770373.65MVEDL
9$97,419,422,774,599$96,595,122,941,562.36$24,792$3,191.91+$97419422.75MVEDL
10$22,936,321,824,645,050$22,832,083,042,276,228.00$30,274$4,689.40+$22936321824.61MVEDL

VEDL vs JNJ: Complete Analysis 2026

VEDLStock

Vedanta Limited operates as a diversified natural resources company in India. The company explores for, develops, produces, processes, and sells oil and gas, zinc, lead, silver, copper, aluminum, iron ore, steel, and power. It is involved in the exploration, development, and production of oil and gas; and exploration, mining, and processing of iron ore, pig iron, and metallurgical coke. The company also operates a thermal coal- based commercial power facility of 600 megawatts (MW) at Jharsuguda in the State of Odisha in eastern India; a 300 MW thermal coal based power plant at Korba; 1,980 MW (three units of 660 MW each) thermal coal- based commercial power facilities; 274MW of wind power plants; and a power plant situated at Mettur Dam in the state of Tamil Nadu in southern India. In addition, it manufactures and supplies billets, TMT bars, wire rods, and ductile iron pipes; engages in the mechanization of coal handling facilities and upgradation of general cargo berth for handling coal at the outer harbour of Visakhapatnam Port on the east coast of India; and provides logistics and other allied services inter alia rendering stevedoring, and other allied services in ports and other allied sectors. Further, the company is involved in manufacturing glass substrates in South Korea and Taiwan. It also has operations in South Africa, Namibia, Ireland, Australia, Liberia, and the United Arab Emirates. The company was incorporated in 1965 and is based in Mumbai, India.

Full VEDL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VEDL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VEDL vs SCHDVEDL vs JEPIVEDL vs OVEDL vs KOVEDL vs MAINVEDL vs ABBVVEDL vs MRKVEDL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.